Pro­to­cols: CRO in­dus­try poised for steady growth as new work in Chi­na ex­plodes (in a good way); Vec­tura dinged on PhI­II Flu­ti­form flop

Shares of the UK’s Vec­tura dropped ear­ly Tues­day af­ter the com­pa­ny con­ced­ed that Flu­ti­form had failed a Phase III study for COPD. The failed study, run by Mundipharm, is scut­tling plans for a reg­u­la­to­ry fil­ing.”Whilst this re­sult is dis­ap­point­ing, Flu­ti­form con­tin­ues to grow strong­ly based on the ap­proved asth­ma in­di­ca­tion, which con­tin­ues to un­der­pin our ex­pec­ta­tions for fu­ture growth of the prod­uct,” Chief Ex­ec­u­tive Of­fi­cer James Ward-Lil­ley said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.